Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors

Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protectin...

Full description

Bibliographic Details

Published in:	Kidney Research and Clinical Practice
Main Authors:	Anthony T. P. Chan, Sydney C. W. Tang
Format:	Article
Language:	English
Published:	The Korean Society of Nephrology 2022-11-01
Subjects:	diabetic kidney disease diabetic nephropathies glucagon-like peptide-1 receptor agonist non-steroidal mineralocorticoid receptor antagonist selective endothelin receptor antagonist sodium-glucose transporter 2 inhibitors
Online Access:	http://www.krcp-ksn.org/upload/pdf/j-krcp-21-285.pdf